Antifungal compositions

Single alkyl chain cationic antifungal compounds like C18-DMS+ and C18-TMA+ effectively target fungal mitochondria, offering improved protection against crop pathogens with reduced toxicity and environmental impact, addressing the limitations of current antifungal agents.

JP2024167417APending Publication Date: 2024-12-03UNIV OF EXETER
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2024156587
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-04-04
Filing Date
2024-09-10
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Current antifungal agents face challenges such as rapid development of fungicide resistance, limited effectiveness against certain fungi, toxicity to mammals, and environmental impact, necessitating the need for novel compounds with novel mechanisms of action, low toxicity, and environmental friendliness.

Method used

Development of single alkyl chain cationic antifungal compounds, specifically C18-DMS+ and C18-TMA+, which target fungal mitochondria by inhibiting oxidative phosphorylation, inducing mitochondrial reactive oxygen species (mROS), and triggering programmed cell death, while having reduced toxicity to humans and the environment.

Benefits of technology

C18-DMS+ and C18-TMA+ demonstrate enhanced antifungal activity against crop pathogens like wheat leaf blight and rice blast, with lower toxicity to humans and Daphnia magna, and induce plant defense responses, providing broad-spectrum protection with multiple modes of action.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024167417000001_ABST
    Figure 2024167417000001_ABST
Patent Text Reader

Abstract

To provide improved cationic surfactant-based antifungal compounds.SOLUTION: The invention provides: an antifungal composition comprising an antifungal compound of formula R-S+(R')2 or R-N+(R')3 (where, R is C17 to C32 straight chain or branched alkyl, and each R' is independently methyl, ethyl, propyl, isopropyl or butyl); and uses of the composition as antifungal agents.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to antifungal compositions comprising single alkyl chain cationic antifungal compounds. The present invention further relates to the use of single alkyl chain cationic compounds as antifungal agents. In particular, the present invention relates to antifungal compositions, methods and uses. [Background technology]

[0002] Fungi are one of the greatest biological challenges for crop health and therefore food security. This threat is further amplified by intensive farming practices such as monocultures, where vast fields of genetically uniform varieties provide an ideal environment for the generation of novel fungicide-resistant strains. In fact, the rate of emergence of fungicide resistance outpaces the rate of antifungal discovery. There are only a handful of "novel" antifungals in the "pipeline", but these are derivatives of commonly used chemicals, such as those targeting specific complexes of ergosterol biosynthesis or the mitochondrial respiratory chain. It is clear that there is an urgent need for novel antifungals with novel mechanisms of action, low mammalian toxicity, and environmental friendliness. Furthermore, there is an increasing need for the discovery of novel antifungals to better protect animals (including humans) against fungal diseases. This is set against the backdrop of emerging antifungal resistance to currently used clinical drugs (azoles). It is also desirable to replace azoles as conservative treatments in wall paints and treated wood.

[0003] One potential target for novel fungicides is fungal mitochondria. These organelles are involved in a wide range of cellular processes, but most importantly provide the enzymes for oxidative phosphorylation that provide the chemical energy to "fuel" the cell. Oxidative phosphorylation depends on electron transport through the mitochondrial respiratory chain complexes of the inner mitochondrial membrane (Hirst, 2013). Fungal mitochondria differ from mammalian mitochondria in the composition and function of their respiratory enzymes, making them attractive targets for novel fungicides. Indeed, two of the three market-leader single-target site fungicides, namely succinate dehydrogenase inhibitors (SDHIs) and strobilurins, disrupt the fungal mitochondrial respiratory chain, targeting respiratory complexes II and III. Mitochondria also generate reactive oxygen species (mROS) at complexes I and III that, when deregulated, can damage proteins and lipids of the inner mitochondrial membrane and trigger apoptotic cell death. Increasing evidence suggests that such a programmed cell death pathway exists in fungi and that targeting this pathway is a promising strategy for developing novel antifungal agents.

[0004] Electron transport through the respiratory chain triggers proton transport across the inner mitochondrial membrane. This leaves the matrix negatively charged and therefore a target for lipophilic cations. These molecules combining a cationic head group with a lipophilic moiety cross the cell membrane and accumulate in the inner mitochondrial membrane, exposing their cationic moiety towards the matrix. This behavior allows the delivery of therapeutic agents to mitochondria, but can also inhibit respiratory enzymes. Such effects on mitochondrial function challenge the use of lipophilic cations in medicine, but it could be the key to their use as plant fungicides / antifungals.

[0005] Lipophilic cations are widely used as "cationic surfactant" disinfectants or as supplements in cosmetics and formulations. Cationic surfactants, especially quaternary ammonium compounds, are recognized for their antibacterial activity but have gained more attention in recent years because of their potential use in the control of human pathogenic fungi. The term cationic surfactant means that these compounds exert their biocidal activity on the surface of pathogens. Indeed, because of their amphiphilic structure, these molecules are expected to insert into the plasma membrane, and all antifungal lipophilic n-alkyl chain cations known so far appear to kill fungal cells by altering the permeability or function of the plasma membrane or by interacting with the fungal cell wall. This includes the lipophilic single alkyl chain cation (SACC) dodecylguanidinium (hereafter referred to as "C12-G+"), the active ingredient of the fungicide Dodine. Dodine is a protective fungicide that is widely used to control fruit scab and foliar diseases in orchards. Although C12-G+ is thought to permeabilize fungal cells, it has also been reported to enter cells and inhibit important metabolic enzymes. It is unclear whether intracellular activity is the primary mechanism of action of C12-G+ or whether it is the result of cell leakage due to increased cell permeability.

[0006] Although C12-G+ is useful as a fungicide, there are some concerns regarding toxicity, and its toxicity to organisms such as Daphnia magna (water fleas) can pose environmental problems, particularly when used as a crop or soil fungicide, as it can result in runoff into bodies of water such as lakes and rivers.

[0007] In addition, while C12-G+ is useful as a fungicide, its effectiveness is limited when used against certain fungi. For example, while nominally effective when used to control Zymoseptoria tritici or Magnaporthe oryzae on wheat and rice, respectively, C12-G+ does not completely control the resulting Septoria wheat leaf blight and rice blast, even at nominally high concentrations (75 μL / ml to 100 μL / ml of C12-G+).

[0008] To ensure future food production, there is a continuing need for more effective treatments against crop pathogens. Due to the rapid development of fungicide resistance in the market-leading chemical sector, the identification of novel fungicides is a priority. These fungicides must (i) be active against crop-destroying pathogens, (ii) target fundamental processes at multiple sites to reduce the emergence of resistance, and (iii) have low toxicity to humans and the environment.

[0009] It would therefore be advantageous to provide additional cationic surfactant-based antifungal compounds that improve the effectiveness of known cationic surfactant-based antifungal compounds, such as C12-G+, against specific fungi or a broad range of fungi. As used herein, the term "antifungal agent" refers to a broad spectrum toxic effect against members of all fungal phyla and oomycetes.

[0010] It would also be advantageous to provide cationic surfactant-based antifungal compounds with reduced environmental and / or human toxicity and preservation of paints and prevent decay of harvested wood products.

[0011] Furthermore, it would be advantageous to provide more effective cationic surfactant-based antifungal compounds, compositions, and treatments that target fungal metabolism at multiple sites in one or more metabolic pathways. Such fungicides would ideally employ novel multi-site mechanisms of action that target fundamental processes in pathogenic cells.

[0012] In addition, it would be advantageous to provide effective cationic surfactant-based biocidal compounds that are effective not only against human and / or animal pathogens, such as pathogenic fungi, but also against plant pathogens.

[0013] It is therefore an object of embodiments of the present invention to overcome or mitigate at least one problem in the prior art, whether described herein or not. Summary of the Invention

[0014] According to a first aspect of the invention, a compound of formula RS + (R')2 or RN + (R')3 (Wherein, R is a C17-C32 straight or branched alkyl; and Each R' is independently methyl, ethyl, propyl, isopropyl, or butyl. The composition comprises an antifungal compound (A) of the formula:

[0015] Compound (A) can include any suitable counteranion, such as bromide, chloride, iodide, hydroxide, sulfate, hydrogen sulfate, and phosphate.

[0016] The composition is preferably an antifungal composition, but may also be an antibacterial or antiarchaeal composition or any combination thereof (e.g., an antifungal and antibacterial composition, or an antifungal, antibacterial and antiarchaeal composition).

[0017] The invention also provides pharmaceutical compositions comprising Compound (A) and a pharma- ceutical compatible carrier or excipient, the use of Compound (A) as an antifungal agent, and methods for destroying, controlling or inhibiting fungi by contacting said fungi with Compound (A).

[0018] In a preferred embodiment, R is a C18-C24, preferably linear alkyl, a C18-C22, preferably linear alkyl, or a C18-C20, preferably linear alkyl. In a particularly preferred embodiment, R is a C18 linear alkyl.

[0019] In certain embodiments, at least one R' is methyl or ethyl, and in preferred embodiments, all R' are methyl.

[0020] Particularly useful as compound (A) in the compositions, uses and methods of the present invention are compounds of the formula:

[0021] [ka]

[0022] and

[0023] [ka]

[0024] (octadecyldimethylsulfonium or "C18-DMS+") and C18-trimethylammonium (octadecyltrimethylammonium or "C18-TMA+") having the formula:

[0025] The composition can comprise, for example, a solution, suspension, emulsion, powder, paste, granules, gel, mousse or dust.

[0026] The composition can include a carrier. The carrier can include a solvent, which can be water or an aqueous solvent. Thus, the composition can be an aqueous composition of compound (A) in water or an aqueous solvent. The aqueous solvent can include water and a co-solvent, which can be selected from, for example, methanol and ethanol.

[0027] The antifungal composition may comprise compound (A) in a concentration of at least 0.1 μg / ml, 0.2 μg / ml, 0.3 μg / ml, 0.4 μg / ml, 0.5 μg / ml, 0.75 μg / ml, 1 μg / ml, 1.5 μg / ml, 2 μg / ml, 2.5 μg / ml, 5 μg / ml, 7.5 μg / ml, 10 μg / ml, 15 μg / ml, 20 μg / ml, 30 μg / ml, 40 μg / ml, 50 μg / ml, 60 μg / ml, 70 μg / ml, 75 μg / ml, at least 100 μg / ml, at least 200 μg / ml, at least 250 μg / ml, at least 500 μg / ml or at least 1000 μg / ml of the composition.

[0028] In some embodiments, the composition comprises Compound (A) at a concentration of 0.1 to 1000 μg / ml, for example, 0.1 to 250 μg / ml, or 0.1 to 200 μg / ml.

[0029] For some uses, such as application of the composition to crops (e.g., wheat, barley, oats, rice, sorghum, plantain, corn, potato, vegetables or fruits), horticultural crops, and trees, the composition may contain compound (A) at a concentration of 10 to 1000 μg / ml, for example, 20 to 500 μg / ml, 25 to 250 μg / ml or 10 to 100 μg / ml.

[0030] In some embodiments, the composition can include an adjuvant. The adjuvant can enhance the effectiveness of the antifungal compound (A). The mechanism of action of a suitable adjuvant includes buffering water to a pH where a particular antifungal compound is most active, adjusting water quality (e.g., when hard water is used to solvate or dilute the antifungal compound, it may reduce the potential inhibitory effect of minerals such as calcium and magnesium), and reducing the surface tension of the water ("wetting agent") so that the antifungal composition has a wider coverage of the surface to which it is applied. The adjuvant can include a solvent that makes the surface (e.g., the leaf cuticle of the plant to which the composition is applied) more permeable to the antifungal compound; or can include nutrients that may assist the antifungal compound when applied to crops or other plants, such as promoting plant growth; or the compound (A) becomes more effective against actively growing plants. Other suitable adjuvants are antifoaming agents, adjuvants that reduce drift during spraying of the antifungal compound, and adjuvants that can reduce evaporation and volatility of the antifungal compound.

[0031] The adjuvant may be a compound selected from a pH buffering agent; a water conditioning agent; a wetting agent; a leaf cuticle and / or cell membrane penetration aid; a plant growth enhancer; an antifoaming agent; a spray drift reducing agent; and / or an evaporation reducing agent; or any combination thereof.

[0032] The adjuvant may be in the form of a crop protection spray additive and / or a surfactant. The adjuvant may increase the permeability of the plant cuticle and / or cell membrane. The adjuvant may be a non-ionic diffusion and penetration aid; and / or may act to reduce the surface tension of the composition.

[0033] Adjuvants can enhance the fungicidal activity of the compound (A), for example by increasing the permeability of the cuticle and / or cell membrane.Adjuvants can enhance the fungicidal activity of the compound (A), for example by increasing the permeability of the plant cuticle and / or cell membrane.

[0034] Adjuvants can be surfactants; additives for crop protection sprays, such as non-ionic spreading and penetrating aids; and / or can act, for example, to reduce the surface tension of the composition.

[0035] The adjuvant may include an active agent adjuvant or a universal adjuvant.

[0036] An active agent adjuvant is a compound that, when added to a composition containing compound (A), enhances its antifungal activity. Active agent adjuvants include, for example, surfactants, oil carriers such as phytobland (non-toxic to plants) oils, crop oils, crop oil concentrates (COC), vegetable oils, methylated seed oils (MSO), petroleum oils, and silicone derivatives, as well as nitrogen fertilizers.

[0037] Universal adjuvants, sometimes called spray modifiers, modify the physical or chemical characteristics of the composition to facilitate application, for example, by enhancing adhesion to plant surfaces so as to reduce the likelihood of spillage, or by increasing its persistence in the environment.

[0038] The oil or oils may be used as adjuvant carriers or diluents for compound (A).

[0039] Salts can also be used as active agent adjuvants, for example to increase the uptake and effectiveness of antifungal compounds on a target surface, material or plant over time.

[0040] One or more surfactant adjuvants may be present in the composition to promote or enhance the emulsifying, dispersing, spreading, adhering or wetting properties of the composition.

[0041] The surfactant reduces the surface tension in the spray droplets of the composition when the composition is applied to a material (such as a surface, plant leaves, etc.), helping the composition to spread and coat the target material with a thin film, resulting in more effective or more rapid absorption of the composition into the material. The surfactant can also affect the absorption of the composition when sprayed onto the stems or leaves of a plant by changing the viscosity and crystal structure of the wax on the surface of the leaves and stems, so that they are more easily penetrated by the compound (A) of the composition.

[0042] The surfactant may be selected to enhance the antifungal properties of the composition through any one or more of: a) spreading the composition more evenly over the material to which it is applied; b) increasing the retention (or "adhesion") of the composition to the material; c) increasing the penetration of the composition through plant hairs, scales, or other leaf surface structures for plant or crop protection applications; d) preventing crystallization of the composition; and / or e) slowing the drying of the composition.

[0043] Each surfactant may be selected from a non-ionic surfactant, an ionic surfactant, an amphoteric or zwitterionic surfactant, or any combination thereof.

[0044] Nonionic surfactants are generally biodegradable and compatible with many fertilizers, and therefore may be preferred in the compositions of the present invention when used in crop or plant protection applications.Some nonionic surfactants are waxy solids and require the addition of co-solvents (such as alcohol or glycol) to solubilize them in liquid.Glycol co-solvents are generally preferred over alcohols, as alcohols are flammable, evaporate quickly, and can increase the number of fine spray droplets (making the formulation more prone to drift when spraying).

[0045] The nonionic surfactant may include organosilicone or silicone surfactants (including siloxanes and organosiloxanes). The organosilicone surfactant significantly reduces the surface tension of the composition, allowing the composition to form a thin layer on the surface of the plant leaves or stems during use. The silicone surfactant may also reduce the surface tension, allowing the composition to penetrate the stomata of the plant leaves. The silicone surfactant also provides a protective effect to the compositions of the present invention by making the compositions very difficult to wash off after they are applied. The silicone surfactant may also affect the amount / rate of absorption of the antifungal compound (A) through the leaf cuticle.

[0046] In other embodiments, the non-ionic surfactant can include a carbamide surfactant (also known as a urea surfactant). The carbamide surfactant can include, for example, monocarbamide dihydrogen sulfate.

[0047] Suitable ionic surfactants include cationic surfactants and anionic surfactants. Suitable cationic surfactants include tallow amine ethoxylates. Suitable anionic surfactants include sulfates, carboxylates, and phosphates bonded to lipophilic hydrocarbons, including, for example, linear alkyl benzene sulfonates.

[0048] Amphoteric surfactants contain both positive and negative charges and typically function similarly to nonionic surfactants. Suitable amphoteric surfactants include, for example, lecithin (phosphatidylcholine) and amidopropylamines.

[0049] Universal adjuvants, sometimes referred to as spray modifiers, can modify the physical or chemical characteristics of the compositions of the present invention to facilitate application of the composition, enhance adhesion to plant surfaces so as to reduce the risk of the composition being removed from said surfaces; or enhance the persistence of the composition in the environment or treatment area in which it is present.

[0050] Examples of different functional categories of universal adjuvants suitable for use in the compositions and uses of the present invention include wetting agents, diffusing agents, drift control agents, foaming agents, dyes, thickeners, deposition agents (adhesives), water conditioning agents, humectants, pH buffers, defoamers, antifoaming agents and UV absorbers.Some universal adjuvants can function in more than one of the above functional categories.Some active agent adjuvants are also universal adjuvants.

[0051] Wetting agents or spreading agents reduce the surface tension in the composition, allowing the composition to form a large thin layer on the leaves and stems of the target plant. These agents can also function as active agent adjuvants (surfactants), since they are typically non-ionic surfactants diluted with water, alcohol, or glycerol. However, some wetting agents or spreading agents only affect the physical properties of the composition, and do not affect the behavior of the composition when in contact with the plant.

[0052] Drift control agents can be used, for example, to reduce spray drift of the composition, which most often occurs when air currents carry fine (<150 μm in diameter) spray droplets away from the target area when the composition is sprayed on plants. Drift control agents modify the viscoelastic properties of the spray solution, resulting in a coarser spray with a larger average droplet size and weight, minimizing the number of small, easily airborne droplets. Suitable drift control agents can include large polymers such as polyacrylamides, polysaccharides, and certain types of gums.

[0053] Suitable deposition agents (adhesives) include, for example, film-forming vegetable gels, emulsifying resins, emulsifying mineral oils, vegetable oils, waxes, and water-soluble polymers. Deposition agents can be used to reduce the loss of the composition from the target plant due to evaporation of the composition from the target surface, or due to the composition beading and running off. Deposition agents are particularly suitable for the compositions of the present invention in the form of dry (wet) powders and granular formulations.

[0054] Defoamers and anti-foaming agents reduce, inhibit or destroy the formation of foam in containers that may contain the compositions of the present invention. Suitable defoamers include, for example, oils, polydimethylsiloxanes and other silicones, alcohols, stearates and glycerol.

[0055] The adjuvant or adjuvants may include BREAK-THRU® S 240, BREAK-THRU® SP 131, BREAK-THRU® SP 133, BREAK-THRU® S 233, BREAK-THRU® OE 446, Aduro (RTM) and / or Transport Ultra (RTM). BREAK-THRU® S 240 is a polyether trisiloxane that provides superspreading and dramatically reduces surface tension. BREAK-THRU® SP 131 is composed of polyglycerol fatty acid esters and polyglycols to improve the performance of antifungal compounds.

[0056] BREAK-THRU® SP 133 is based on polyglycerol esters and fatty acid esters. BREAK-THRU® S 233 is a non-ionic trisiloxane surfactant that increases pesticide spray deposition and improves penetration of pesticide actives into plant tissue. BREAK-THRU® OE 446 is a polyether polysiloxane.

[0057] Transport Ultra (RTM) contains a blend of non-ionic surfactants, ammoniated ionic, water conditioners and anti-foam agents.

[0058] Aduro (RTM) contains monocarbamide dihydrogen sulfate and an alkylamine ethoxylate.

[0059] In some preferred embodiments, at least one adjuvant is selected from silicones, siloxanes, alkylamine ethoxylates or carbamides. The adjuvants are particularly useful for enhancing the effect of antifungal compounds or, conversely, for increasing or accelerating the uptake of antifungal compounds by plants, particularly vascular plants and mosses.

[0060] In some embodiments, the adjuvant may include a non-ionic surfactant; and / or an anti-foaming agent; and / or ammonium ions; and / or a water conditioner; and / or a polyether-polymethylsiloxane copolymer; and / or a polyether polysiloxane; and / or a polyglycerol fatty acid ester and a polyglycerol; and / or a polyglycerol ester and a fatty acid ester; and / or a non-ionic trisiloxane.

[0061] In a preferred embodiment, the composition comprises at least one surfactant, which may be a non-ionic surfactant. In some embodiments, the composition comprises at least one silicone or siloxane, which may act as a surfactant and / or an antifoaming agent and / or a wetting agent.

[0062] The antifungal composition may contain one or more additional antifungal agents in addition to compound (A). The additional antifungal agents may be selected from azoles, amino derivatives, strobilurins, specific anti-oidium compounds, aniline-pyrimidines, benzimidazoles and analogues, dicarboximides, polyhalogenated fungicides, systemic acquired resistance (SAR) inducers, phenylpyrroles, acylalanines, anti-peronosporic compounds, dithiocarbamic acids, arylamidines, phosphorous acid and its derivatives, fungicidal copper compounds, vegetable oils (botanical components), chitosan, sulfur-based fungicides, fungicidal amides, and nitrogen heterocycles, or any combination thereof.

[0063] According to a second aspect of the invention, a compound of formula RS + (R')2 or RN + (R')3 (Wherein, R is a C17-C32 straight or branched alkyl; and Each R' is independently methyl, ethyl, propyl, isopropyl, or butyl. The present invention provides the use of the biocidal compound (A) of the formula (I) as an antifungal, antibacterial or antiarchaeal agent.

[0064] Compound (A) may be as described and defined above for the first aspect of the invention, and is preferably octadecyldimethylsulfonium or octadecyltrimethylammonium. Compound (A) may be present in the antifungal composition of the first aspect of the invention.

[0065] According to a third aspect of the present invention there is provided a compound of formula RS for use in the treatment of a disease, preferably a fungal disease. + (R')2 or RN + (R')3 (Wherein, R is a C17-C32 straight or branched alkyl; and Each R' is independently methyl, ethyl, propyl, isopropyl, or butyl. There is provided a biocidal compound (A) of the formula:

[0066] Compound (A) may be as described and defined above, and is preferably octadecyldimethylsulfonium or octadecyltrimethylammonium. Compound (A) may be present in the antifungal composition of the first aspect of the invention.

[0067] The disease may be a phytopathogenic disease. The phytopathogenic disease may be a fungal disease of a plant or its seeds, such as cereals (such as wheat, barley, rye, oats, rice, corn, sorghum, etc.), fruit trees (such as apple, pear, plum, peach, almond, cherry, banana, grape, strawberry, raspberry, blackberry, etc.), citrus trees (such as orange, lemon, mandarin, grapefruit, etc.), legumes (such as beans, peas, lentils, soybeans, etc.), vegetables (such as spinach, lettuce, asparagus, cabbage, carrot, onion, tomato, potato, eggplant, pepper, etc.), cucurbits (such as pumpkin, zucchini, cucumber, melon, watermelon, etc.), oleaginous plants (such as sunflower, rapeseed, peanut, castor, coconut, etc.), tobacco, coffee, tea, cocoa, sugar beet, sugar cane, cotton, and or horticultural plants.

[0068] Phytopathogenic fungal and oomycete species against which compound (A) can be used include Basidiomycetes, Ascomycetes, Fungi or Fungi Imperfecti, Chytridiomycetes, Zygomycetes, Microsporidia and Oomycetes.These include, but are not exclusive to, Puccinia spp., Ustilago spp., Tilletia spp., Uromyces spp., Phakopsora spp., Rhizoctonia spp., Erysiphe spp., Sphaerotheca spp., Podosphaera spp., Uncinula spp., Helminthosporium spp., Rhynchosporium spp., Pyrenophora spp., spp.), Monilinia spp., Sclerotinia spp., Septoria spp. (Mycosphaerella spp., Zymoseptoria spp.), Venturia spp., Botrytis spp., Alternaria spp., Fusarium spp., Cercospora spp., Cercosporella herpotrichoides, Colletotrichum spp., Pyricularia oryzae, Sclerotium spp., Phytophthora spp., Pythium spp., Plasmopara viticola, Peronospora spp., Pseudoperonospora cubensis, and Bremia lactucae.

[0069] Specific fungal species infections against which compound (A) can be used include Erysiphe graminis in cereals, Zymoseptoria tritici in cereals (particularly wheat), Magnaporthe oryzae in cereals (particularly rice), Erysiphe cichoracearum and Sphaerotheca fuliginea in cucurbits, Podosphaera leucotricha in apple, Uncinula necator in grapevine, Venturia inaequalis in apple, and Zymoseptoria tritici in cereals (particularly wheat). inaequalis (black scab), Helminthosporium spp. in cereals, Septoria nodorum in wheat, Botrytis cinerea (grey mold) in strawberries and grapes, Cercospora arachidicola in peanuts, Pseudocercosporella herpotrichoides in wheat and barley, Pyricularia oryzae in rice, Fusarium spp. and Verticillium spp. in various plants, and Alternaria spp. in fruits and vegetables.

[0070] Examples of plant fungal diseases against which the compound (A) can be used include, but are not limited to, lesions (particularly wheat leaf blight), rot, fusarium wilt, canker rot, microsclerotinia rot, Thielaviopsis root rot, blight (particularly rice blast), sclerotinia rot, smut, soybean rust, cereal rust, potato blight, powdery mildew, clubroot, anthracnose, wilt, Rhizoctonia root rot, bottom rot, spot rot, ring spot, white leaf blight, Septoria spot, ring spot, black spot, stem blight, black knot, ergot, leaf blisters, black spot, snow mold, sooty mold and verticillium wilt.

[0071] In some embodiments, the disease may be an animal pathogenic fungal disease, which in some embodiments may be independently selected from the diseases in the table below.

[0072] [Table 1] TIFF2024167417000005.tif75160

[0073] Thus, compound (A) can be used to treat many common human and animal fungal infections including candidiasis, tinea gracilis and dermatophytosis.

[0074] According to a fourth aspect of the invention, the fungus is of the formula RS + (R')2 or RN + (R')3 (Wherein, R is a C17-C32 straight or branched alkyl; and Each R' is independently methyl, ethyl, propyl, isopropyl, or butyl. The present invention provides a method for destroying, controlling or inhibiting fungi by contacting the fungus with a compound (A) of the formula:

[0075] Compound (A) may be as described and defined above, and is preferably octadecyldimethylsulfonium or octadecyltrimethylammonium. Compound (A) may be present in the antifungal composition of the first aspect of the invention.

[0076] The method may comprise contacting the fungus with the antifungal composition of the first aspect of the invention.

[0077] Controlling or inhibiting fungi can include controlling the growth and / or life span of fungi.

[0078] Methods can include destroying, controlling or suppressing fungal-infected plants (including cuttings or growing plants or plant parts), seeds, animals (including humans, non-human mammals and other non-human animals), soil or ecosystems.

[0079] When applying compound (A) or a composition thereof to soil or ecosystem ground, the application rate may be from 0.02 to 3 kg or more of active ingredient per hectare, depending on the type of effect desired.

[0080] The plant can be a vascular plant, and in some embodiments is selected from crops or trees.Compound (A) or the composition comprising compound (A) can be applied by spraying or dusting the plant with the active ingredient, or by treating the seed of the plant with the active ingredient.They can be applied before or after the infection of the plant or seed by fungus or fungi.

[0081] In other embodiments, the method can include destroying, controlling or inhibiting fungi in building or construction materials. The building or construction materials can include wood (raw or treated), wall coverings, bricks, blocks, gypsum board, floor coverings or paints.

[0082] Suitable wall coverings include, for example, cladding, wallpaper, ceramic wall coverings (such as tiles), rubber, polymer coatings, paints, varnishes and lacquers. Floor coverings include, for example, carpets, linoleum, wooden boards or blocks, ceramic tiles, varnishes and lacquers. Compound (A) or a composition comprising compound (A) can be applied by spraying or dusting the coating onto the wall covering or floor covering, or by impregnating the covering with compound (A) or a composition comprising compound (A).

[0083] Compositions containing compound (A), such as solutions, emulsions, suspensions, powders, dusts, pastes and granules, can be applied to building or construction materials, for example, by spraying, misting, dusting, sprinkling, covering or watering.

[0084] According to a fifth aspect of the invention, a compound of formula RS + (R')2 or RN + (R')3 (Wherein, R is a C17-C32 straight or branched alkyl; and Each R' is independently methyl or ethyl. The present invention provides a building or construction material or composition comprising compound (A) of the formula:

[0085] The compound (A) can, for example, be impregnated into or included in a coating on a building or construction material or composition. The building or construction material can be selected from wood (raw or treated), wall coverings, bricks, gypsum board, floor coverings or paints.

[0086] The building or construction material or composition may be a material or composition which has been treated (sprayed, coated or impregnated) by the method of the fourth aspect of the invention.

[0087] According to a sixth aspect of the invention, a compound of the formula R-S+(R')2 or R-N+(R')3 (Wherein, R is a C17-C32 straight or branched alkyl; and Each R' is independently methyl, ethyl, propyl, isopropyl, or butyl. There is provided a pharmaceutical composition comprising the antifungal compound (A) of the formula (I) and a pharma- ceutical acceptable carrier or excipient.

[0088] Compound (A) may be as described and defined above for the first aspect of the invention, and in preferred embodiments is octadecyldimethylsulfonium ("C18-DMS+") or octadecyltrimethylammonium (C18-TPP+).

[0089] The pharmaceutical composition of the second aspect of the present invention can be used to treat humans or non-human animals, particularly non-human mammals.Suitable non-human mammals include, for example, sheep, goats, cows, pigs, dogs, cats and horses.Other animals can include chickens, geese, ducks, turkeys or other birds.

[0090] The pharma- ceutical carrier or excipient can be a solvent, preferably an aqueous solvent. In some embodiments, the aqueous solvent can be water. In other embodiments, the aqueous solvent can include a mixture of water and a co-solvent. The co-solvent can be an alcohol, and can be selected from methanol, ethanol, and combinations.

[0091] The pharmaceutical composition may be in a topical administration format. Thus, the pharmaceutical composition may be a topically administrable pharmaceutical composition.

[0092] The term "topical administration" relates to the application of a substance to a body surface, such as the skin. In a preferred embodiment, topical administration is on the skin (directly on the surface of the skin), also known as "dermal administration."

[0093] The pharmaceutical composition may be provided in a form suitable for topical administration, including, but not limited to, an ointment, gel, cream, lotion, foam, spray, mousse, patch, powder, paste, hydrogel, emulsion (including oil-in-water, water-in-oil, oil-in-water-in-oil, water-in-oil-in-water emulsions), or any combination thereof. In some preferred embodiments, the pharmaceutical composition is provided as a cream, ointment, lotion or gel, most preferably as a cream or ointment.

[0094] In some embodiments, the carrier or diluent may be an aqueous carrier or diluent, and may include, for example, water itself, such as deionized water, or a mixture of water and another solvent. Suitable mixtures include, for example, water and a polar protic solvent, such as methanol, ethanol, propanol, isopropanol, and butanol.

[0095] Alternatively, the carrier or diluent may comprise a hydrophobic carrier or diluent and may be selected from fats and oils, natural waxes, petroleum waxes, hydrocarbons, or any suitable mixtures thereof. Alternatively, the carrier or diluent may comprise an organic solvent.

[0096] Suitable natural waxes include beeswax (including white or yellow beeswax), carnauba wax, wool wax, lanolin (refined or anhydrous lanolin), or any suitable combination thereof.

[0097] Suitable petroleum waxes include solid paraffin and microcrystalline wax.

[0098] Suitable hydrocarbons include liquid paraffin, soft paraffin (white or yellow petrolatum), white petrolatum, yellow petrolatum, or any suitable combination thereof.

[0099] The pharmaceutical compositions may include any other suitable carrier or diluent, such as those described in the British Pharmacopoeia, 2017 edition or the European Pharmacopoeia, 9th edition.

[0100] Suitable organic solvents include, but are not limited to, non-polar solvents, polar aprotic solvents, and polar protic solvents.

[0101] Suitable non-polar solvents include alkanes (such as hexane and pentane), cycloalkanes (such as cyclopentane and cyclohexane), benzene, toluene, chloroform, diethyl ether, and dichloromethane.

[0102] Suitable polar aprotic solvents include tetrahydrofuran, ethyl acetate, acetone, dimethylformamide, acetonitrile, dimethylsulfoxide, and propylene carbonate.

[0103] Polar protic solvents include, but are not limited to, alcohols (such as methanol, ethanol, propanol, isopropanol, and butanol), formic acid, and acetic acid.

[0104] The use of organic solvents is particularly useful for pharmaceutical compositions in the form of a spray, for example, as defined above. A spray can be used to ensure that hard-to-reach areas of the skin, such as between hooves or under skin folds, are coated with the pharmaceutical composition.

[0105] In some embodiments, compound (A) can be encapsulated. In some embodiments, compound (A) can be incorporated into liposomes. For both encapsulated and liposomally entrapped compound (A), the pharmaceutical composition of the present invention can include an aqueous carrier, including water itself. Compound (A) can be microencapsulated. Encapsulants suitable for encapsulation or microencapsulation include, for example, yeast cells, exine shell material (such as from pollen grains), and the like.

[0106] The pharmaceutical compositions of the present invention may further comprise one or more pharmaceutical excipients. Suitable pharmaceutical excipients include, but are not limited to, emulsifiers, surfactants, solvents, cosolvents, preservatives, stabilizers, buffers, solubilizers, dispersants, antioxidants, thickeners, emollients, lubricants, emollients, and one or more additional skin healing or conditioning agents.

[0107] The pharmaceutical compositions of the present invention may further comprise one or more pharmaceutical excipients. Suitable pharmaceutical excipients include, but are not limited to, emulsifiers, surfactants, solvents, cosolvents, preservatives, stabilizers, buffers, solubilizers, dispersants, antioxidants, thickeners, emollients, lubricants, emollients, and one or more additional skin healing or conditioning agents.

[0108] Suitable preservatives are, for example, quaternary ammonium compounds such as benzalkonium chloride (N-benzyl-N-(C8-C18-alkyl)-N,N-dimethylammonium chloride), benzoxonium chloride, benzethonium chloride, cetrimide (hexadecyl-trimethylammonium bromide), sepazonium chloride, cetylpyridinium chloride, domiphen bromide, and the like; quaternized ammonium cyclodextrin compounds (e.g., QACD compounds as described in U.S. Pat. No. 3,453,257 or U.S. Pat. No. 5,241,059); thiosalicyclic compounds such as thimerosal, phenylmercuric nitrate, phenylmercuric acetate, or phenylmercuric borate, a stabilized oxychloro complex; a polyglycol-polyamine condensate resin; a stabilized hydrogen peroxide produced from a hydrogen peroxide source to provide an effective trace amount of resulting hydrogen peroxide, such as sodium perborate tetrahydrate; and / or any suitable combination thereof.

[0109] Preferred preservatives are quaternary ammonium compounds, particularly benzalkonium chloride, cetrimide and phenylethyl alcohol. If necessary, a sufficient amount of preservative is added to the pharmaceutical composition to ensure protection against cross contamination during use.

[0110] Suitable surfactants or emulsifiers include, but are not limited to, nonionic surfactants, anionic surfactants, cationic surfactants, amphoteric surfactants, and zwitterionic surfactants.

[0111] Suitable cationic surfactants include, for example, quaternary ammonium salts. Suitable anionic surfactants include, for example, carboxylates, such as sodium or potassium salts of fatty acids; and sulfates, such as, for example, sodium laureth sulfate and sodium dodecyl sulfate, of fatty acids.

[0112] Suitable nonionic surfactants include, but are not limited to, ethers of fatty alcohols, polyol esters, polyoxyethylene esters, poloxamers, etc. Suitable polyoxyethylene esters include, but are not limited to, polyethylene glycerol (PEG). Suitable polyol esters include, but are not limited to, glycol and glycerol esters, and sorbitan derivatives.

[0113] It will be understood that the pharmaceutical composition of the present invention for topical application should not contain any ingredient that may cause skin irritation, even in long-term use.It is necessary to avoid compounds that may cause sensitization.Therefore, balanced amphoteric surfactants may be preferred as surfactants.

[0114] The term "amphoteric surfactant" is well known to those skilled in the art. Such surfactants (which may also be known as amphoteric surfactants) carry at least one anionic group and at least one cationic group, and therefore, depending on the pH, can have anionic, nonionic, or cationic properties. If the isoelectric point of the molecule occurs at pH 7, the molecule is said to be balanced. Amphoteric surfactants can have the properties of detergents and disinfectants. Balanced amphoteric surfactants can be particularly non-irritating to the skin, and are therefore preferred in the topical pharmaceutical compositions of the present invention.

[0115] Suitable amphoteric surfactants include amino carboxylic acids, amino propionic acid derivatives, imidazoline derivatives, dodecane, pendecamine or long chain betaines, or cocamidopropyl betaine.

[0116] Suitable complexing agents include, but are not limited to, those selected from disodium ethylenediaminetetraacetate, ethylenediaminetetraacetic acid (EDTA); phosphonic acids or chelating agents having a phosphonic acid group, preferably organic phosphonic acids, in particular aminotri(lower alkylene phosphonic acids); for example, α-, β- or γ-cyclodextrin, for example alkylated, hydroxyl alkylated, carboxy-alkylated or alkyloxycarbonyl-alkylated derivatives, or cyclodextrins such as mono- or diglycosyl-α-, β- or γ-cyclodextrin, mono- or dimaltosyl-α-, β- or γ-cyclodextrin or panosyl-cyclodextrin, and any mixtures thereof.

[0117] The pharmaceutical compositions of the present invention may further include an antioxidant such as, for example, ascorbic acid, acetylcysteine, cysteine, sodium bisulfate, butylated hydroxyanisole, butylated hydroxytoluene, or natural or synthetic vitamin E derivatives such as alpha-tocopherol or alpha-tocopherol acetate.

[0118] In yet another embodiment, the pharmaceutical compositions comprising the compound (A) described herein may also comprise a second agent (second active ingredient, second active agent) that possesses a desired therapeutic or prophylactic activity other than the antifungal compound (A). Such second active agents may include, but are not limited to, additional antifungal agents, antibacterial agents, antibodies, antiviral agents, anticancer agents, analgesics (e.g., nonsteroidal anti-inflammatory agents (NSAIDs), acetaminophen, opioids, COX-2 inhibitors), immunostimulants (e.g., cytokines), hormones (natural or synthetic), central nervous system (CNS) stimulants, antiemetics, antihistamines, erythropoietin, complement stimulants, sedatives, muscle relaxants, anesthetics, anticonvulsants, antidepressants, antipsychotics, and combinations thereof.

[0119] According to a seventh aspect of the present invention, there is provided a compound (A) for use in treating a fungal condition in a human or mammal. Compound (A) may be a pharmaceutical composition as described above for the sixth aspect of the present invention. The fungal condition in a human or mammal may be as described above.

[0120] In order that the invention may be more clearly understood, embodiments thereof will now be described, by way of example only, with reference to the accompanying drawings, in which: [Brief description of the drawings]

[0121] [Figure 1] Figure 1 is a table (Table 1) illustrating the relative effectiveness of C12-G+, C18-TMA+ and C18-DMS+ in relation to antifungal activity and toxicity for two fungal infections of plants (Z. tritici on wheat and M. oryzae on rice); [Diagram 2] Figure 2 contains four graphs showing the inhibitory effects of the SACCs C18-TMA+ and C18-DMS+ on the mitochondrial potential of two plant pathogenic and two human pathogenic fungi; [Diagram 3] Figure 3 contains three graphs summarizing results from LIVE / DEAD staining experiments used to assess the mortality of C18-TMA+ and C18-DMS+ in one phytopathogenic fungus causing wheat leaf blight and two Candida species causing infectious diseases in humans; [Figure 4] FIG. 4 is a graph illustrating an additional mechanism of action (mitochondrial reactive oxygen species generation) of C18-DMS+ in three phytopathogenic fungi that cause rice blast (Magnaporthe oryzae), wheat leaf spot (Zymoseptoria tritici) and corn smut (Ustilago maydis); as well as in two Candida species that cause infectious disease in humans; [Diagram 5] FIG. 5 is a graph illustrating an additional mechanism of action of C18-DMS+ (induction of programmed cell death in Zymoseptoria tritici as shown by two staining methods); [Figure 6] FIG. 6 is a graph illustrating the increased potential of C18-DMS+ for protecting crops against Septoria wheat leaf blight and rice blast; [Figure 7] Figure 7 is a graph illustrating an additional mechanism of action of C18-DMS+ (induction of the plant defense system); [Figure 8] FIG. 8 is a table (Table 2) comparing the relative efficacy and toxicity of C12-G+ and C18-DMS+ using data from the table in FIG. 1; and [Figure 9] FIG. 9 illustrates a model of the effect of SACC on fungal oxidative phosphorylation. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0122] Determination of the effect of dodecyl-guanidinium (dodine) on the integrity of fungal plasma membranes We investigated the physiological effects and mechanism of action (hereafter "MoA") of the known antifungal compound dodine (hereafter "C12-G+") against the basidiomycete corn smut fungus U. maydis and the ascomycete septoria wheat leaf blight fungus Z. tritici. Both fungi are crop pathogens of major economic importance, and therefore cell biological techniques and tools, including fluorescent markers for live cell imaging of all organelles, have been developed in recent years.

[0123] On agar plates supplemented with C12-G+, fungal growth was inhibited in a concentration-dependent manner, with Z. tritici being more inhibited by C12-G+ than U. maydis. 12 -G+ was approximately four times more sensitive (concentration required for 50% inhibition of proliferation: EC 50 , Wheat leaf blight fungus (Z. tritici): 0.6μg / ml; EC 50, U. maydis: 2.3 μg / ml. The toxicity of C12-G+ was then tested using live / dead staining in liquid cultures of cells expressing the fluorescent plasma membrane marker GFP-Sso1. In these assays, live cells were green and turned yellow to red upon death. Again, C12-G+ was more effective in Z. tritici than in U. maydis, killing >80% of all cells after 1 h at 100 μg / ml (compared to approximately 15% death in U. maydis under the same conditions). Upon 30-45 min of incubation with C12-G+ at up to 50 μg / ml (U. maydis) or 100 μg / ml (Z. tritici), most cells remained viable, suggesting that investigating cells under these conditions would provide insight into the primary cellular response to the drug.

[0124] C12-G+ is thought to act on the fungal plasma membrane. Denuded cells expressing the fluorescent marker GFP-Sso1 were monitored to measure changes in the appearance of the plasma membrane. High concentrations of C12-G+ induced the formation of GFP-Sso1 "patches" at the cell periphery of both fungi, but Z. tritici was approximately two-fold less sensitive to C12-G+ (at 50 μg / ml). Electron microscopy studies revealed that C12-G+-treated cells formed plasma membrane invaginations. These structures were recognized by an antibody against GFP, suggesting that they represent GFP-Sso1 patches. Since it is thought that plasma membrane invaginations may be the result of excessive insertion of C12-G+ into the fungal plasma membrane, the lateral diffusion of GFP-Sso1 in C12-G+-treated cells was monitored. The reporter was photobleached at the plasma membrane and fluorescence recovery was monitored, indicating lateral movement of unbleached GFP-Sso1. Addition of ≥10 μg / ml C12-G+ significantly reduced the mobility of GFP-Sso1 in U. maydis, but this effect was not observed in C12-G+-treated Z. tritici cells, suggesting a difference in the impact of SACC on the plasma membrane of the two fungi.

[0125] We then measured drug-induced ion leakage from cells by visualizing changes in the membrane potential of C12-G+-treated cells using bis-(1,3-dibutylbarbituric acid) trimethine oxonol, DiBAC4(3), a voltage-sensitive fluorescent probe that stains only depolarized cells. High concentrations of C12-G+ increased the number of depolarized cells in U. maydis, but had little effect in Z. tritici. This result confirms that C12-G+ had a stronger effect on the plasma membrane of U. maydis than that of Z. tritici. However, the low effect of C12-G+ on Z. tritici plasma membrane does not correspond to its toxicity in this fungus (see above). Therefore, the effect on the plasma membrane is most likely not the major MoA of C12-G+ in fungi.

[0126] Determining the effect of C12-G+ on fungal mitochondrial organization and respiration The lipophilic cation C12-G+ was tested to determine whether it targeted negatively charged fungal mitochondria. Accumulation of lipophilic cations in the inner membrane induces changes in mitochondrial ultrastructure. The effect of C12-G+ was tested using a fungal strain containing a fluorescent marker for mitochondria (fluorescent reporter protein). Low concentrations of C12-G+ severely affected mitochondrial shape and induced fragmentation of the organelle. Electron microscopy revealed that the organization of the mitochondrial inner membrane was altered, with disorganized and swollen cristae. This result supports the concept that C12-G+ targets mitochondria and inserts into the inner membrane. This membrane contains the protein complexes of the respiratory chain that generate the membrane potential necessary to synthesize ATP. We also determined whether C12-G+ interfered with this oxidative phosphorylation by staining C12-G+-treated cells with the mitochondrial potential dye tetramethylrhodamine methyl ester (TMRM) and found that even small amounts of C12-G+ depolarized mitochondria in U. maydis. Measurements of cellular oxygen consumption in cell suspensions confirmed that C12-G+ inhibited cellular respiration. A similar effect on membrane potential was observed in Z. tritici, which was approximately four-fold more sensitive to C12-G+ treatment than U. maydis. This corresponds well to the approximately four-fold increase in mortality of Z. tritici cells in the presence of C12-G+ (see above). Therefore, the inhibitory effect on ATP production may be the primary MoA of C12-G+ in fungi.

[0127] Effects on mitochondria may explain the fungal specificity of C12-G+. To test this, we treated mammalian skin C109 fibroblasts with C12-G+ and monitored the effects on mitochondrial morphology and membrane potential.

[0128] C12-G+ had little effect on mitochondrial organization at concentrations up to 20 μg / ml, but above this concentration it caused organelle fragmentation and swollen cristae. This suggests that C12-G+ inserts into the human mitochondrial inner membrane, but at concentrations about 5-fold higher than in Z. tritici (shown in Table 1 in Figure 1; compare EC50 values ​​for mitochondrial fragmentation). There was also a modest effect of C12-G+ on mitochondrial membrane potential - human cells were about 50-fold less sensitive to lipid cations (shown in Table 1 in Figure 1; compare EC50 for depolarization in Table 1). Thus, the inhibitory effect on mitochondrial respiration probably supports the specificity of C12-G+ for fungi.

[0129] Determining the effect of longer alkyl chains on antifungal activity An assay was established to quantitatively monitor the effect of C12-G+ on mitochondria, and the synthesis and identification of a novel single alkyl chain cation (hereafter, "SACC") was performed. It has been reported that the cationic head group and the length of the alkyl chain determine the activity of SACC. Therefore, SACCs were synthesized combining different cationic (and one anionic) moieties, including a sulfonium head group, with alkyl chains of various lengths, and their effects were tested against Z. tritici mitochondria. The extent of fragmentation was monitored as an indicator of insertion into the mitochondrial membrane, and mitochondrial depolarization was measured using TMRM staining.

[0130] The following compounds were synthesized: (i) C12-Alkyl cations with various moieties: (Dodecyltriphenylphosphonium - henceforth "C12-TPP+"); Dodecyltrimethylammonium - after this, "C12-TMA+"; Dodecyltriethylammonium = C12-TEA+; dodecyldimethylsulfonium - hereafter referred to as "C12-DMS+"); (ii) Lipophilic cations with short C6-alkyl chains: (Hexyltrimethylammonium - henceforth "C6-TMA"); hexyldimethylsulfonium (hereafter "C6-DMS+") and (iii) Lipophilic cations with longer C18-alkyl chains: (Octadecyltrimethylammonium - henceforth "C18-TMA+"); Octadecylmethylsulfonium - after this "C18-DMS+"; (iv) Lipophilic alkyl anions: Dodecyl phosphate (hereafter "C12-PO4-") (v) Symmetric lipophilic cations having a dimethylsulfonium moiety at each end of a C12-alkyl chain: (Dodecane-1,12-diylbis(dimethylsulfonium - hereafter "++(DMS)2-C12").

[0131] At low concentrations (2.5 μg / ml), only molecules of groups (i) and (iii) induced significant mitochondrial fragmentation.

[0132] The EC50 of each of the compounds in groups (i) and (iii) against Z. tritici was tested, and the following results were obtained:

[0133] EC50[C12-G+]:6.63μg / ml;EC50[C12-TPP+]:6.63μg / ml;EC50[C12-TMA+]:3.85μg / ml;EC50[C12-TEA+] :2.38μg / ml;EC50[C12-DMS+]:7.39μg / ml;EC50[C18-TMA+]:1.55μg / ml;EC50[C18-DMS+]:1.72μg / ml).

[0134] The results show that only cationic amphiphilic molecules with long alkyl chains insert into the mitochondrial membrane. However, when tested for mitochondrial depolarization, only C12-TPP+ and the two C18-alkyl chain cations (C18-TMA+, C18-DMS+) showed significant inhibition of mitochondrial respiration in Z. tritici. All three SACCs were tested for their ability to depolarize mitochondria in the plant pathogens Zymoseptoria triciti (which causes septoria wheat leaf blight) and Magnaporthe oryzae (which causes rice blast). In addition, C18-TMA+, C18-DMS+ were tested for similar effects on mitochondrial potential in Candida albicans and Candida glabrata (both of which cause a variety of infectious candidiasis). All compounds reduced mitochondrial potential (Figure 2), which required the synthesis of ATP (a major function of mitochondria). This supports the conclusion that inhibition of respiration is the primary physiological effect of SACC. Consistent with interference with this important cellular pathway, C18-TMA+, C18-DMS+ effectively killed Z. tritici (12-14 h exposure, 10 μg / ml) and both Candida species (Figure 3, results from LIVE / DEAD staining experiments), with C18-DMS+ being the most toxic to C. albicans (5 h exposure, 100 μg / ml). Both C18-TMA+ and C18-DMS+ were 2- to 7-fold more toxic to Z. tritici than C12-G+.

[0135] As a result of these experiments it was apparent that the C6 SACCs and some of the C12 SACCs were not suitable as effective antifungal agents, so only the specific C12 and both C18 SACCs were used in subsequent testing.

[0136] Determination of the toxicity of C18-TMA+ and C18-DMS+ in human cells and Daphnia magna Low toxicity to humans and the environment is an important requirement for fungicides. Therefore, the toxicity of C12-TPP+, C18-TMA+ and C18-DMS+ was tested on C109 human skin fibroblast cells. After incubation with various concentrations of the compounds, mitochondrial organization and mitochondrial membrane potential were monitored. These experiments revealed that C12-TPP+ had little effect on human mitochondrial organization (EC[C12-TPP+]: 5.62 μg / ml), but affected human mitochondrial respiration at low concentrations ((EC50 C12-TPP+: 0.355 μg / ml), and was therefore considered too toxic to be an effective antifungal agent for most applications.

[0137] In contrast, the C18-alkyl chain cations C18-TMA+ and C18-DMS+ induced changes in mitochondrial morphology in fungi at 1.5–1.8 μg / ml, whereas human mitochondria were approximately 29-fold less sensitive to both SACCs compared to C12-G+ (shown in Table 1, Figure 1). Furthermore, both compounds inhibited mitochondrial respiration in Z. tritici at much lower concentrations than in human cells, suggesting that the specificity of both SACCs is approximately 75-fold (C18-TMA+) and 53-fold (C18-DMS+) higher for fungi than for humans (shown in Table 1, Figure 1). Similar inhibition of mitochondrial respiration was observed in the human pathogens Candida albicans and Candida glabrata (Figure 2).

[0138] In addition, we investigated the toxicity of C12-G+, C18-TMA+ and C18-DMS+ to the water flea Daphnia magna. This freshwater crustacean is well established as a reporter organism for toxicity testing. First, Daphnia magna were treated with 1 μg / ml of C12-G+, C18-TMA+ and C18-DMS+ for 30 min, followed by visualization of mitochondrial potential by TMRM. This treatment had no effect on crustacean motility. Daphnia incubated with solvent control (no SACC) showed red fluorescence, suggesting that their mitochondria were healthy. C12-G+ treated organisms lost most of the signal, suggesting that even small amounts of C12-G+ rapidly affect mitochondrial respiration in Daphnia magna. In contrast, both C18-alkyl chain cations had little or no effect on mitochondrial potential.

[0139] Daphnia were then treated with various concentrations of all three SACCs for 24 hours, and their locomotor behavior and "escape response" were monitored as indicators of mortality. In these experiments, C12-G+ killed all Daphnia magna at approximately 1 μg / ml, while C18-TMA+ and C18-DMS+ had little effect at this concentration. Higher amounts of both C18 SACCs ultimately killed Daphnia magna, with C18-TMA+ being 1.8-fold more toxic than C18-DMS+. However, both C18-alkyl cations were approximately 5-8-fold less toxic than C12-G+ (shown in Table 1 in Figure 1).

[0140] In summary, toxicity experiments showed that C18-TMA+ and C18-DMS+ exhibited low toxicity to cultured human cells and to freshwater zooplankton, especially compared to C12-G+ and C12-TPP+.

[0141] Determine whether C18 SACC inhibits the mitochondrial respiratory chain in multiple ways The results of the above experiments showed that C12-G+, C18-TMA+ and C18-DMS+ depolarize the inner mitochondrial membrane of plant and human pathogenic fungi. In mammalian cells, the lipophilic cation C12-TPP+ exerts such an effect by acting as a protonophore. We designed to test whether C12-G+, C18-TMA+ and C18-DMS+ have a similar mechanism of action in Z. tritici. The protonophore increases the formation of mitochondrial reactive oxygen species (mROS), which can be detected in live cells using the fluorescent dye dihydrorhodamine-123 (DHR-123). Z. tritici cells were treated with the protonophore carbonyl cyanide m-chlorophenylhydrazone (CCCP) for 30 min to confirm the increase in mitochondrial reactive oxygen species (hereafter "mROS") levels. We then measured mROS levels in cells treated with C12-G+ and C18-TMA+. In contrast to CCCP, both compounds reduced mROS concentrations, suggesting that they act differently from CCCP (Figure 4, Zymoseptoria tritici). Thus, protonophore activity may be unique in C12-TPP+.

[0142] C12-G+ and C18-TMA+ significantly reduced mROS in Z. tritici cells (Figure 4). A similar reduction in mROS was observed in C18-TMA+-treated cells of the human pathogenic fungus C. glabrata (Figure 4). The major sites of mROS formation in mitochondria are respiratory complex I and, to a lesser extent, respiratory complex III. The specific complex I inhibitors rotenone and antimycin A were used to block the activity of complex I and III, respectively. Blocking complex I reduced mROS levels and was 3-4 times more effective than C12-G+ and C18-TMA+. Thus, both SACCs inhibit complex I, but not as strongly as rotenone. The inhibitor antimycin A blocks the binding of reduced coenzyme Q at complex III and thus increases mROS in mammalian cells. Antimycin A-treated Z. tritici cells produced an increase in mROS, which was significantly reduced in the presence of C12-G+ and C18-TMA+. Thus, in Z. tritici, both SACCs appear to reduce the delivery of electrons via coenzyme Q. This supports the idea that SACC can interfere with the early steps of electron transport in the inner mitochondrial membrane.

[0143] Determine whether C18-DMS+ induces mROS production and programmed fungal cell death mROS production in C18-DMS+ treated cells was also determined in the plant pathogenic fungi Z. tritici, U. maydis, and M. oryzae, as well as the human pathogens C. albicans and C. glabrata. Surprisingly, C18-DMS+ acted differently than C12-G+ and C18-TMA+, and mROS levels were significantly induced by this compound in all tested fungi, as shown in Figure 4. In Z. tritici, this effect mimicked that of CCCP, while 24 h incubation with CCCP reduced mROS, whereas 24 h treatment with C18-DMS+ induced further mROS production. C18-DMS+ did not increase mROS levels when Z. tritici cells were incubated with rotenone, a complex I inhibitor. It therefore appears that C18-DMS+ induces mROS production at respiratory complex I. Next, the importance of the alkyl chain length in the ability of C18-DMS+ to induce mROS formation was investigated. To this end, a C16-alkyl chain dimethylsulfonium cation (C16-DMS+) was also synthesized. Both this compound and C12-DMS+ (see above) were tested for their ability to produce mROS in Z. tritici. Incubation with both SACCs for 30 min did not increase mROS levels at either 5 μg / ml or 20 μg / ml. It therefore appears that a longer than C16-alkyl chain length is necessary for alkyl-DMS+ compounds to be able to induce mROS.

[0144] Increasing evidence suggests that fungi can undergo programmed cell death, and mROS is thought to induce this pathway. Therefore, programmed cell death was examined in Z. tritici cells treated with C12-G+, C18-TMA+, and C18-DMS+. A fluorescent caspase activity marker, CaspACE™ FITC-VAD-FMK, capable of detecting apoptotic death in fungi, was used. To distinguish early apoptotic cells from postmortem apoptotic cells, co-staining with propidium iodide, a plasma membrane integrity reporter, was performed. After 24 h of treatment with C18-DMS+, a significant increase in early apoptotic cells was observed (CaspACE™ FITC-VAD-FMK positive, but propidium iodide negative; shown in Figure 5). Only a few apoptotic cells were observed after incubation with C12-G+ or C18-TMA+. This result was confirmed using Annexin-V-fluorescein staining of phosphatidylserine exposed at the plasma membrane in early apoptotic cells. Again, as shown in Figure 5, membrane-associated fluorescence of apoptotic cells was only observed in C18-DMS+ treated cells. Thus, C18-DMS+ induced mROS production results in activation of programmed cell death pathways in Z. tritici and most likely in other plant and human pathogens.

[0145] Determination of C18-DMS+ and C18-TMA+ protection of plants against Septoria wheat leaf blight and rice blast infection As determined above, C12-G+, C18-TMA+, and C18-DMS+ depolarize mitochondrial membranes and inhibit ATP synthesis, thereby cutting off the pathogen's "energy supply." In addition, C18-DMS+ induces mROS production, which causes oxidative damage within mitochondria and triggers programmed cell death. This multiple mechanism of action, which enhanced protection against plant pathogens in leaf infection assays, was investigated. Wheat plants with leaves pretreated with SACC were all spray-inoculated with Z. tritici IPO323. In addition, the ability of C12-G+, C18-TMA+, and C18-DMS+ to protect rice leaves against the rice blast fungus, Magnaporthe oryzae, was tested. All SACCs tested were found to inhibit germination and abrogate appressorium formation of germinating M. oryzae - developmental stages essential for subsequent rice infection. Within 3 h on glass slides, conidia treated with the solvent control germinated and formed appressoria. In fact, three SACCs inhibited this, with C18-TMA+ being slightly more effective than C18-DMS+. This was accompanied by mitochondrial fragmentation, altered organization of the inner membrane and mitochondrial depolarization. mROS levels were also determined in the presence of all SACCs, and only C18-DMS+ was found to induce mROS production. These results support the findings with Z. tritici and suggest that C18-DMS+ may have an enhanced potential to protect against rice blast. In further preparation for plant infection experiments, we investigated whether wheat and rice leaves were susceptible to C12-G+, C18-TMA+, or C18-DMS+. Whole plants were sprayed "leaf-drop" with small amounts of the solvent methanol (=negative control), 10% Tween20 (=positive control), and water containing 1000 μg / ml of C12-G+, C18-TMA+, C18-DMS+, respectively, in solvent / water. Despite these high concentrations, no SACC induced chlorosis or necrosis in wheat or rice leaves after 7 days. This indicates that none of C12-G+, C18-TMA+ or C18-DMS+ is phytotoxic.

[0146] Quantitative wheat and rice leaf infection assays were then performed. All three SACCs at various concentrations were sprayed on wheat and rice and the plants were left for 24 hours before Z. tritici (strain IPO323) and M. oryzae (strain Guy11) were applied and the appearance of lesions / symptoms quantified. In control experiments, Z. tritici formed black spots on chlorotic leaves after 21 days, representing melanized pycnidia, a symptom of Septoria wheat leaf blight. M. oryzae infection resulted in the formation of brown lesions after 4 days of incubation. Treatment of leaves of both crops with C12-G+, C18-TMA+ or C18-DMS+ inhibited the development of symptoms. This protective effect was concentration-dependent. As shown in Figure 6, even at high concentrations, C12-G+ did not completely inhibit infection by Z. tritici or M. oryzae, and C18-TMA+ did not completely protect against Septoria wheat leaf blight and rice blast. In contrast, C18-DMS+ almost abolished symptom development at 75 and 100 μg / ml in wheat and rice, making it particularly useful as an antifungal agent for crop protection. Indeed, direct comparison of symptom formation at high concentrations revealed that C18-DMS+ provided significantly better protection against Z. tritici and M. oryzae (shown in Table 1 in Figure 1 and Table 2 in Figure 6).

[0147] The observed enhancement of plant protection by C18-DMS+ may be due to multiple MoAs in fungal pathogens. However, it is possible that C18-DMS+ may also induce innate defenses in plants, thereby alerting the plant to potential pathogen attack. Such a stimulus results in an oxidative burst, including the production of hydrogen peroxide, protecting the plant from pathogen invasion. The three SACCs were tested to determine whether they induce such early plant defense responses by staining rice leaves with diaminobenzidine (DAB) after treatment with 150 μg / ml of C12-G+, C18-TMA+, and C18-DMS+. This dye reacts with localized H2O2, resulting in a reddish-brown precipitate indicative of a plant defense response. Solvent-treated leaves showed little DAB precipitation, but treatment with 15 mM salicylic acid resulted in a brown color. Although C12-G+ and C18-TMA+ treatments induced slight peroxide production after 6 h, a much stronger DAB response was observed when leaves were sprayed with C18-DMS+ (shown in Figure 7 and Table 1 in Figure 1), suggesting that C18-DMS+ primes the plant against pathogen attack and enhances the protective activity of this SACC.

[0148] Uses and Advantages of the Invention Novel fungicides are needed to protect calorie crops from fungal diseases and thus ensure food security and protect human / animal and ecosystem health. The challenge is therefore to discover antifungals that combine low toxicity to humans with small impacts on the environment. Moreover, such chemicals need to be resilient and have a multisite mechanism of action that cannot be easily overcome by the emergence of resistance. Mitochondria are valuable targets for fungicide development because these organelles not only provide cellular ATP but also control lipid homeostasis and programmed fungal cell death. A novel group of SACCs with alkyl chain lengths greater than 16 have been synthesized and used as antifungals. In particular, two SACCs, C18-TMA+ and C18-DMS+, combine high antifungal activity with relatively low toxicity in humans, Daphnia magna and plants. C18-DMS+, in particular, exhibits low toxicity and combats fungal pathogens through multiple pathways, namely: (i) inhibition of oxidative phosphorylation, (ii) induction of damaging mROS, (iii) induction of fungal apoptosis, and (iv) stimulation of plant defense.

[0149] Single alkyl chain cations target fungal mitochondria. Lipophilic cations have long been known for their antibacterial toxicity and relatively recently have been recognized as antifungal compounds for medical applications. Among the biocidal cations are SACCs, which combine a cationic head group with a long n-alkyl chain. This simple amphiphilic organization suggests that SACCs insert into membranes. Indeed, many studies have reported that SACCs, such as CTAB (cetyltrimethylammonium bromide) or C12-G+ (dodecylguanidinium, also known as dodine), modify the permeability or function of the plasma membrane. Before SACCs reach the plasma membrane, they must cross the fungal cell wall. During this passage, they may change the surface charge of the fungal cell, which has been explained as the main effect supporting the fungal toxicity of these compounds. Antifungal lipid cations, including SACCs, are therefore thought to act at the fungal cell surface, which is reflected in the name "cationic surfactants".

[0150] However, many results contradict this putative MoA in fungi. Early reports on the mechanism of action of dodine showed that at high concentrations, this fungicide penetrates the plasma membrane - but fungal cells were already dead. Other reports suggest that dodine inhibits key metabolic enzymes, suggesting that lipophilic cations cross the plasma membrane and exert their major fungitoxic effects inside fungal cells. Once across the plasma membrane, positively charged SACC accumulates in the negatively charged mitochondrial matrix and may be inserted into the inner mitochondrial membrane. The results detailed herein support this notion. High concentrations of C12-G+ affect the plasma membrane of fungi (EC50 in Z. tritici is approximately 20-50 μg / ml), whereas all tested SACCs induced mitochondrial fragmentation and altered the appearance of the inner mitochondrial membrane (EC50 in Z. tritici is <7 μg / ml). Furthermore, all seven tested long-chain SACCs showed a stronger inhibition of mitochondrial respiration (EC50 in Z. tritici is <2 μg / ml). These results were confirmed in U. maydis and M. oryzae using selected SACCs. Thus, SACCs appear to target mitochondria and interfere with oxidative phosphorylation in fungi.

[0151] Multiple effects of single alkyl chain cations on mitochondrial respiration. Electron transport through mitochondrial respiratory chain complexes pumps protons into the mitochondrial inner space, leaving the matrix negatively charged. This spatial charge separation generates the proton motive force used for the synthesis of ATP. SACC depolarizes the inner membrane, thus disabling ATP production, and the energy supply of the fungal cell is effectively "cut off". Previous studies with isolated mitochondria have shown that C12-TPP+ depolarizes mitochondria by interacting with negatively charged fatty acid residues, which leads to a mild uncoupling effect. Thus, the tested SACC may promote uncontrolled passage of protons into the mitochondrial matrix. However, monitoring of mROS production in Z. tritici revealed that SACC acts differently from the protonophore CCCP. Furthermore, the uncoupling activity of C12TPP+ requires a delocalized cationic charge, whereas SACC has a localized charge. Thus, C12-TPP+ may have unique effects on the fungal mitochondrial respiratory chain, which may explain its high toxicity. However, the results cannot exclude a mild uncoupling effect of the SACC tested.

[0152] Without being bound to any theory, it is believed that lipophilic cations can inhibit respiratory complex I and / or complex III in isolated mitochondria. In fungi, complex I is complemented by alternative dehydrogenases specific to fungi. Both reduce coenzyme Q, which transfers electrons to complex III. As a by-product, both complexes I and III produce low levels of mROS. C12-G+ and C18-TMA+ reduce basal levels of mROS in Z. tritici and also reduce antimycin A-induced mROS formation at complex III. Thus, SACC may interfere with early steps in the electron transfer chain. One possibility is that SACC inserted into the membrane alters the surface charge of these membrane-bound enzymes, thereby interfering with their activity. Furthermore, SACC may alter membrane fluidity, thereby interfering with the assembly and function of complex I, since diffusion through the inner membrane has been shown to be necessary and dependent on the lipid composition of the inner membrane. Furthermore, lipophilic cations may bind directly to proteins of respiratory complexes. Indeed, a specific complex I inhibitor, 2-decyl-4-quinazolinylamine (DQA), binds directly to purified complex I and is predicted to be a lipophilic cation at physiological pH. Thus, inference at earlier steps in the respiratory chain via inhibiting fungal alternative NADH dehydrogenases and / or fungal-specific proteins of complex I may explain the specificity of SACC for fungal cells.

[0153] C18-DMS+ and C18-TMA+ combat fungal pathogens through multiple mechanisms of action. As shown in the figure, the most effective antifungal SACC against Z. tritici is C18-DMS+. This compound is more fungitoxic and inhibits respiration more effectively than C12-G+ (shown in Table 2 in Figure 8), a known fungicide used to control pathogens in orchards. Importantly, the enhanced antifungal performance of C18-DMS+ was accompanied by reduced toxicity to human cells and Daphnia magna. Although C18-DMS+ was less effective at inhibiting oxidative phosphorylation than the quaternary ammonium cation C18-TMA+ (shown in Table 1 in Figure 1), it effectively protected wheat and rice from fungal pathogens significantly better than the other C12-G+ and C12-TPP+. This improved protective performance may be due to the multiple ways in which C18-DMS+ and C18-TMA+ "attack" fungal pathogens. In particular, C18-DMS+ showed fungal inhibition and killing through multiple actions, namely: (i) like other SACCs, this compound inhibits oxidative phosphorylation, thus depriving fungal cells of ATP; (ii) it induces mROS production, possibly involving complex I - which causes oxidative damage to mitochondrial lipids and proteins; (iii) C18-DMS+ partitions pathogens into irreversible programmed cell death pathways; (iv) finally, C18-DMS+ exhibits an oxidative burst that triggers the formation of hydrogen peroxide in plants, triggering an early plant defense response. Thus, C18-DMS+ primes plants against pathogen attack and reduces the chances of successful fungal infection.

[0154] C18-TMA+ and C18-DMS+ differ only in their head groups, suggesting that the additional physiological effects in fungal cells are due to the dimethylsulfonium moiety. The key to the physiological effects of C18-DMS+ in fungi is its ability to induce mROS production. This was observed in Z. tritici, M. oryzae, and U. maydis, and is therefore a general feature of C18-DMS+. Interestingly, the dimethylsulfonium moiety does not induce mROS when attached to a C12- or C16-alkyl chain, even at high concentrations. This result indicates that the length of the alkyl chain is important for the function of the cationic head group. This finding is surprising, since even the slightly shorter hydrophobic C16-alkyl chain was not effectively incorporated into the inner mitochondrial membrane, and only chain lengths longer than C16 showed mROS induction.

[0155] conclusion C18-DMS+ and C18-TMA+ were surprisingly much more effective antifungals than either of the C6 or C12 alkyl chain length compounds tested. Both C18-DMS+ and C18-TMA+ were more effective overall (and in the case of C18-DMS+, in virtually all modes of action) against U. maydis, Z. tritici, and M. oryzae than the other SACCs tested. Taken together, the pathogens tested challenge crops that provide two-thirds of the calories in the human diet. Table 1 in Figure 1 shows the improved efficacy and lower toxicity of both C18-DMS+ and C18-TMA+ compared to dodine, a well-known SACC antifungal compound, and Table 2 in Figure 8 also shows how much more effective C18-DMS+ is compared to dodine.

[0156] Second, both C18-DMS+ and C18-TMA+ target the fungal respiratory chain in different ways, with C18-DMS+ triggering mROS at respiratory complex I, which is predicted to damage mitochondrial proteins and lipids, but also triggering apoptosis in fungi, as shown in Figure 9.

[0157] Finally, the tested C18 SACC showed relatively low toxicity in cultured human cells and Daphnia magna (compared to known SACC fungicides), and C12-TPP+ showed unexpectedly high toxicity to cultured human cells; whereas C12-G+ did not adequately protect plants against pathogens.

[0158] The identification of C18-DMS+ and C18-TMA+ as particularly effective antifungals acting in different modes of action and significantly less toxic (human and / or environmental toxicity) than C12-G+, and the resulting identification of C17-C32 alkyl chain cations with dialkyl- or trialkyl-substituted cation moieties, indicates that the compounds of the invention and compositions of the invention hold great potential as fungicides in crop protection.

[0159] Other uses Due to their low toxicity to humans and efficacy against fungi, the C17-C32 SACC compositions of the invention can be used in the treatment (prevention or improvement) of building and construction materials, particularly wood, wall coverings (such as wallpaper), floor coverings (such as carpet or linoleum), and paints. The SACC compositions can be incorporated during the manufacture of the building or construction materials, or can be impregnated or coated into the materials after manufacture.

[0160] The SACC compositions of the present invention can also be used as cleaning or sterilizing compositions against both fungi and other microorganisms (e.g., oomycetes, archaea) and can be used prophylactically, for example, to prevent the growth of pathogens on or remove infestations from surfaces.

[0161] The SACC of the present invention can further be used on soil or other plant growth media to eliminate fungi, limit the spread of fungi, or control the growth of fungi. It can be applied in any suitable manner, such as, for example, by spraying or dusting.

[0162] The C18-DMS+, C18-TMA+ and other C17+SACC compositions of the present invention can be incorporated into pharmaceutical compositions, particularly for topical administration to humans, non-human mammals and other animals.

[0163] The above embodiments have been described by way of example only: many variations are possible without departing from the scope of the invention as defined in the appended claims.

Claims

1. Formula R-S + (R') 2 or R-N + (R') 3 wherein R is a C17-C32 straight chain or branched alkyl; and Each R' is independently methyl, ethyl, propyl, isopropyl, or butyl. and a pharma- ceutical compatible carrier or excipient.

2. 2. The pharmaceutical composition of claim 1, wherein R is a C18 alkyl group.

3. 3. The pharmaceutical composition of claim 1 or 2, wherein each R' is methyl.

4. 4. The pharmaceutical composition of claim 1, wherein the antifungal compound is octadecyltrimethylammonium or octadecyldimethylsulfonium.

5. 5. The pharmaceutical composition of claim 1, wherein the antifungal compound comprises a counterion selected from chloride, bromide, iodide, hydroxide, sulfate, phosphate, hydrogen sulfate or acetate.

6. 6. The pharmaceutical composition of claim 1, wherein the antifungal compound is dissolved or suspended in an aqueous carrier.

7. 7. The pharmaceutical composition of claim 1, wherein the pharma- ceutical acceptable carrier or excipient comprises a solvent, a co-solvent, an oil, a fat, a natural wax, a petroleum wax, a hydrocarbon, or any suitable combination thereof.

8. 8. The pharmaceutical composition of claim 1, wherein the pharma- ceutical acceptable carrier or excipient comprises an organic solvent.

9. 9. The pharmaceutical composition according to any one of claims 1 to 8, which is a topically administrable pharmaceutical composition.

10. 10. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is an ointment, cream, or spray.

11. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is encapsulated.

12. 12. A pharmaceutical composition according to any one of claims 1 to 11, comprising one or more further antifungal agents.

13. The present invention relates to a method for treating fungal diseases in humans or non-human animals, comprising administering to said animals a compound of the formula R-S. + (R') 2 or R-N + (R') 3 wherein R is a C17-C32 straight chain or branched alkyl; and Each R' is independently methyl, ethyl, propyl, isopropyl, or butyl. Antifungal compounds.

14. 14. The antifungal compound of claim 13, wherein the compound is octadecyltrimethylammonium or octadecyldimethylsulfonium.

15. The present invention relates to a compound of formula R-S as an antifungal agent for the treatment of fungal diseases in humans or non-human animals. + (R') 2 or R-N + (R') 3 wherein R is a C17-C32 straight chain or branched alkyl; and Each R' is independently methyl, ethyl, propyl, isopropyl, or butyl. Use of compounds.

16. The fungus is represented by the formula R-S + (R') 2 or R-N + (R') 3 wherein R is a C17-C32 straight chain or branched alkyl; and Each R' is independently methyl, ethyl, propyl, isopropyl, or butyl.

4. A method of treating a fungal infection in a human or non-human animal comprising destroying, controlling or inhibiting fungi by contacting said animal with an antifungal compound of the formula:

17. The method of claim 16, wherein the antifungal compound is applied as a composition containing 0.1 to 200 μg / ml of the compound.

18. 18. The method of claim 16 or 17, wherein the antifungal compound is applied topically as a composition.

19. 19. The method of claim 18, wherein the composition is as defined in any one of claims 1 to 12.

20. 14. The use or pharmaceutical composition according to any one of claims 11 to 13, wherein the antifungal compound is octadecyltrimethylammonium or octadecyldimethylsulfonium.

Citation Information

Patent Citations

  • Fungicidal organic phosphorus derivative salt

    JP1984141557A

  • Mixed alkylsulfonium salt of n-phosphonomethylglycine

    JP1984212498A

  • disinfectant

    JP2004534718A

  • New antimicrobial agent

    JP2008044881A

  • Formulations containing antimicrobial compositions

    JP2010539276A